

REMARKS

Claims 130, 178, 335 have been amended to address the Examiner's comments as discussed in more detail below.

Objections

Claim 178 has been amended to recited "under" as requested by the Examiner.

Rejections

Claim 130 has been amended to change SEQ ID NO:63 to SEQ ID NO:66, as suggested by the Examiner.

Claim 335 has been amended in analogous fashion to claim 64 in the previous response.

Remarks regarding claim 48 and analogous claims

The Examiner says that the language of claim 48 does not include vector sequences within the scope of the claim. In reply, applicants would state that the scope is more accurately characterized as neither requiring nor excluding vector sequences. It is evident from claim 51 that the isolated nucleic acid of claim 48 can exist as part of a vector. Thus, claim 48 is open to this possibility, but does not require, the recited isolated nucleic acid being part of a vector.

Double patenting

A terminal disclaimer is provided with respect to USSN 11/090,399.

Applicants also update the list of related applications and patents drawn to the Examiner's attention in the last response. 09/730,329 was inadvertently omitted from the previous list. 09/723,722 has now granted as US 7,115,410. 11/090,866 has now granted as US

Appl. No. 09/471,669
Amdt. dated October 22, 2007
Reply to Office Action of June 22, 2007

PATENT

7,252,963. 11/090,399 has now granted as US 7,262,043. 11/090,872 has granted as US 7,276,349

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300
Attachments
JOL:sjj
61161895 v1